

- S1. Brantley-Finley, C., Lyle, C.S., Du, L., Goodwin, M.E., Hall, T., Szewedo, D., Kaushal, G.P., and Chambers, T.C. 2003. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. *Biochem Pharmacol* 66:459-469.
- S2. Karpinich, N.O., Tafani, M., Rothman, R.J., Russo, M.A., and Farber, J.L. 2002. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. *J Biol Chem* 277:16547-16552.
- S3. Siddik, Z.H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* 22:7265-7279.
- S4. Enokido, Y., Araki, T., Aizawa, S., and Hatanaka, H. 1996. p53 involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule neurons. *Neurosci Lett* 203:1-4.
- S5. Boyer, J., McLean, E.G., Aroori, S., Wilson, P., McCulla, A., Carey, P.D., Longley, D.B., and Johnston, P.G. 2004. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. *Clin Cancer Res* 10:2158-2167.
- S6. Capizzi, R.L. 1996. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. *Invest New Drugs* 14:249-256.
- S7. Yamaguchi, H., Chen, J., Bhalla, K., and Wang, H.G. 2004. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. *J Biol Chem* 279:39431-39437.
- S8. Haridas, V., Higuchi, M., Jayatilake, G.S., Bailey, D., Mujoo, K., Blake, M.E., Arntzen, C.J., and Gutterman, J.U. 2001. Avicins: triterpenoid saponins from *Acacia victoriae* (Benth) induce apoptosis by mitochondrial perturbation. *Proc Natl Acad Sci U S A* 98:5821-5826.
- S9. Hanausek, M., Ganesh, P., Walaszek, Z., Arntzen, C.J., Slaga, T.J., and Gutterman, J.U. 2001. Avicins, a family of triterpenoid saponins from *Acacia victoriae* (Benth), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. *Proc Natl Acad Sci U S A* 98:11551-11556.
- S10. Wang, J.L., Liu, D., Zhang, Z.J., Shan, S., Han, X., Srinivasula, S.M., Croce, C.M., Alnemri, E.S., and Huang, Z. 2000. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. *Proc Natl Acad Sci U S A* 97:7124-7129.
- S11. Tzung, S.P., Kim, K.M., Basanez, G., Giedt, C.D., Simon, J., Zimmerberg, J., Zhang, K.Y., and Hockenbery, D.M. 2001. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. *Nat Cell Biol* 3:183-191.
- S12. Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., and Yuan, J. 2001. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. *Nat Cell Biol* 3:173-182.
- S13. Real, P.J., Cao, Y., Wang, R., Nikolovska-Coleska, Z., Sanz-Ortiz, J., Wang, S., and Fernandez-Luna, J.L. 2004. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. *Cancer Res* 64:7947-7953.
- S14. Yang, B., Liu, D., and Huang, Z. 2004. Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. *Bioorg Med Chem Lett* 14:1403-1406.
- S15. Shangary, S., Oliver, C.L., Tillman, T.S., Cascio, M., and Johnson, D.E. 2004. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. *Mol Cancer Ther* 3:1343-1354.
- S16. Walensky, L.D., Kung, A.L., Escher, I., Malia, T.J., Barbuto, S., Wright, R.D., Wagner, G., Verdine, G.L., and Korsmeyer, S.J. 2004. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. *Science* 305:1466-1470.
- S17. Adams, D.M., Ji, W., Barth, R.F., and Tjarks, W. 2000. Comparative in vitro evaluation of dequalinium B, a new boron carrier for neutron capture therapy (NCT). *Anticancer Res* 20:3395-3402.
- S18. Modica-Napolitano, J.S., Koya, K., Weisberg, E., Brunelli, B.T., Li, Y., and Chen, L.B. 1996. Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. *Cancer Res* 56:544-550.
- S19. Fantin, V.R., Berardi, M.J., Scorrano, L., Korsmeyer, S.J., and Leder, P. 2002. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. *Cancer Cell* 2:29-42.

- S20. Fantin, V.R., and Leder, P. 2004. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. *Cancer Res* 64:329-336.
- S21. Propper, D.J., Braybrooke, J.P., Taylor, D.J., Lodi, R., Styles, P., Cramer, J.A., Collins, W.C., Levitt, N.C., Talbot, D.C., Ganesan, T.S., et al. 1999. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. *Ann Oncol* 10:923-927.
- S22. Britten, C.D., Rowinsky, E.K., Baker, S.D., Weiss, G.R., Smith, L., Stephenson, J., Rothenberg, M., Smetzer, L., Cramer, J., Collins, W., et al. 2000. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. *Clin Cancer Res* 6:42-49.
- S23. Schempp, C.M., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Kiss, J., Termeer, C.C., Gilb, B., Kaufmann, T., Borner, C., Sleeman, J.P., et al. 2002. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Oncogene* 21:1242-1250.
- S24. Dona, M., Dell'Aica, I., Pezzato, E., Sartor, L., Calabrese, F., Della Barbera, M., Donella-Deana, A., Appendino, G., Borsarini, A., Caniato, R., et al. 2004. Hyperforin inhibits cancer invasion and metastasis. *Cancer Res* 64:6225-6232.
- S25. Morgan, J., and Oseroff, A.R. 2001. Mitochondria-based photodynamic anti-cancer therapy. *Adv Drug Deliv Rev* 49:71-86.
- S26. Sabzevari, O., Galati, G., Moridani, M.Y., Siraki, A., and O'Brien, P.J. 2004. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. *Chem Biol Interact* 148:57-67.
- S27. Ellerby, H.M., Arap, W., Ellerby, L.M., Kain, R., Andrusiak, R., Rio, G.D., Krajewski, S., Lombardo, C.R., Rao, R., Ruoslahti, E., et al. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. *Nat Med* 5:1032-1038.
- S28. Don, A.S., Kisker, O., Dilda, P., Donoghue, N., Zhao, X., Decollogne, S., Creighton, B., Flynn, E., Folkman, J., and Hogg, P.J. 2003. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. *Cancer Cell* 3:497-509.
- S29. Nicolaou, K., Pfeifferkorn, J., Schuler, F., Roecker, A., Cao, G., and Casida, J. 2000. Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase. *Chem Biol* 7:979-992.
- S30. Salomon, A.R., Voehringer, D.W., Herzenberg, L.A., and Khosla, C. 2000. Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase. *Proc Natl Acad Sci U S A* 97:14766-14771.
- S31. Tuquet, C., Dupont, J., Mesneau, A., and Roussaux, J. 2000. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. *Cell Biol Toxicol* 16:207-219.
- S32. Belzacq, A.S., Jacotot, E., Vieira, H.L., Mistro, D., Granville, D.J., Xie, Z., Reed, J.C., Kroemer, G., and Brenner, C. 2001. Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. *Cancer Res* 61:1260-1264.
- S33. Belzacq, A.S., El Hamel, C., Vieira, H.L., Cohen, I., Haouzi, D., Metivier, D., Marchetti, P., Brenner, C., and Kroemer, G. 2001. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. *Oncogene* 20:7579-7587.
- S34. Jan, G., Belzacq, A.S., Haouzi, D., Rouault, A., Metivier, D., Kroemer, G., and Brenner, C. 2002. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. *Cell Death Differ* 9:179-188.
- S35. Marchetti, P., Zamzami, N., Joseph, B., Schraen-Maschke, S., Mereau-Richard, C., Costantini, P., Metivier, D., Susin, S.A., Kroemer, G., and Formstecher, P. 1999. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. *Cancer Res* 59:6257-6266.
- S36. Hail, N., Jr., Youssef, E.M., and Lotan, R. 2001. Evidence supporting a role for mitochondrial respiration in apoptosis induction by the synthetic retinoid CD437. *Cancer Res* 61:6698-6702.
- S37. Costantini, P., Jacotot, E., Decaudin, D., and Kroemer, G. 2000. Mitochondrion as a novel target of anticancer chemotherapy. *J Natl Cancer Inst* 92:1042-1053.
- S38. Zhang, T.D., Chen, G.Q., Wang, Z.G., Wang, Z.Y., Chen, S.J., and Chen, Z. 2001. Arsenic trioxide, a therapeutic agent for APL. *Oncogene* 20:7146-7153.

- S39. Huan, S.Y., Yang, C.H., and Chen, Y.C. 2000. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. *Leuk Lymphoma* 38:283-293.
- S40. Sordet, O., Rebe, C., Leroy, I., Bruey, J.M., Garrido, C., Miguet, C., Lizard, G., Plenchette, S., Corcos, L., and Solary, E. 2001. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. *Blood* 97:3931-3940.
- S41. Ling, Y.H., Liebes, L., Zou, Y., and Perez-Soler, R. 2003. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. *J Biol Chem* 278:33714-33723.
- S42. Jung, L., Holle, L., and Dalton, W.S. 2004. Discovery, Development, and clinical applications of bortezomib. *Oncology (Huntingt)* 18:4-13.
- S43. Hirsch, T., Decaudin, D., Susin, S.A., Marchetti, P., Larochette, N., Resche-Rigon, M., and Kroemer, G. 1998. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. *Exp Cell Res* 241:426-434.
- S44. Banker, D.E., Cooper, J.J., Fennell, D.A., Willman, C.L., Appelbaum, F.R., and Cotter, F.E. 2002. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. *Leuk Res* 26:91-106.
- S45. Decaudin, D., Castedo, M., Nemati, F., Beurdeley-Thomas, A., De Pinieux, G., Caron, A., Pouillart, P., Wijdenes, J., Rouillard, D., Kroemer, G., et al. 2002. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. *Cancer Res* 62:1388-1393.
- S46. Machida, K., Hayashi, Y., and Osada, H. 2002. A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability transition-independent mechanism. *J Biol Chem* 277:31243-31248.
- S47. Watabe, M., Machida, K., and Osada, H. 2000. MT-21 is a synthetic apoptosis inducer that directly induces cytochrome c release from mitochondria. *Cancer Res* 60:5214-5222.
- S48. Pisha, E., Chai, H., Lee, I.S., Chagwedera, T.E., Farnsworth, N.R., Cordell, G.A., Beecher, C.W., Fong, H.H., Kinghorn, A.D., Brown, D.M., et al. 1995. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. *Nat Med* 1:1046-1051.
- S49. Fulda, S., and Debatin, K.M. 2000. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. *Med Pediatr Oncol* 35:616-618.
- S50. Fulda, S., Jeremias, I., and Debatin, K.M. 2004. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. *Oncogene* 23:7611-7620.
- S51. Fulda, S., Susin, S.A., Kroemer, G., and Debatin, K.M. 1998. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. *Cancer Res* 58:4453-4460.
- S52. Thurnher, D., Turhani, D., Pelzmann, M., Wannemacher, B., Knerer, B., Formanek, M., Wacheck, V., and Selzer, E. 2003. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. *Head Neck* 25:732-740.
- S53. Miyato, Y., and Ando, K. 2004. Apoptosis of human melanoma cells by a combination of lonidamine and radiation. *J Radiat Res (Tokyo)* 45:189-194.
- S54. Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A., and Cignetti, F. 2003. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. *Drugs Today (Barc)* 39:157-174.
- S55. Oudard, S., Carpentier, A., Banu, E., Fauchon, F., Celerier, D., Poupon, M.F., Dutrillaux, B., Andrieu, J.M., and Delattre, J.Y. 2003. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. *J Neurooncol* 63:81-86.
- S56. Matsumoto, S., Isshiki, A., Watanabe, Y., and Wieloch, T. 2002. Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. *Life Sci* 72:591-600.
- S57. Yoshimoto, T., Uchino, H., He, Q.P., Li, P.A., and Siesjo, B.K. 2001. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. *Brain Res* 899:148-158.
- S58. Serkova, N.J., Christians, U., and Benet, L.Z. 2004. Biochemical mechanisms of cyclosporine neurotoxicity. *Mol Interv* 4:97-107.

- S59. Chen, Z., Siu, B., Ho, Y.S., Vincent, R., Chua, C.C., Hamdy, R.C., and Chua, B.H. 1998. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. *J Mol Cell Cardiol* 30:2281-2289.
- S60. Rajesh, K.G., Sasaguri, S., Suzuki, R., and Maeda, H. 2003. Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. *Am J Physiol Heart Circ Physiol* 285:H2171-2178.
- S61. Okatani, Y., Wakatsuki, A., Enzan, H., and Miyahara, Y. 2003. Edaravone protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat liver. *Eur J Pharmacol* 465:163-170.
- S62. Smith, R.A., Porteous, C.M., Coulter, C.V., and Murphy, M.P. 1999. Selective targeting of an antioxidant to mitochondria. *Eur J Biochem* 263:709-716.
- S63. Smith, R.A., Porteous, C.M., Gane, A.M., and Murphy, M.P. 2003. Delivery of bioactive molecules to mitochondria in vivo. *Proc Natl Acad Sci U S A* 100:5407-5412.
- S64. Kelso, G.F., Porteous, C.M., Coulter, C.V., Hughes, G., Porteous, W.K., Ledgerwood, E.C., Smith, R.A., and Murphy, M.P. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. *J Biol Chem* 276:4588-4596.

